newsfilter
← Latest News
ACCESS Newswire·

Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

Term loan maturity extended by 12 months to June 2029Principal balance on term loan expanded to $13.0 million from $11.1 million currentlyExpanded revolving line of credit facility by $1.5 millionExpanded facilities